JP2013520424A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520424A5 JP2013520424A5 JP2012553967A JP2012553967A JP2013520424A5 JP 2013520424 A5 JP2013520424 A5 JP 2013520424A5 JP 2012553967 A JP2012553967 A JP 2012553967A JP 2012553967 A JP2012553967 A JP 2012553967A JP 2013520424 A5 JP2013520424 A5 JP 2013520424A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- powder
- ray diffraction
- substantially similar
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=*)c(OC)c2)nc1 Chemical compound COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=*)c(OC)c2)nc1 0.000 description 1
- ZLHFILGSQDJULK-UHFFFAOYSA-M COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=O)c(OC)c2)nc1 Chemical compound COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=O)c(OC)c2)nc1 ZLHFILGSQDJULK-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30604710P | 2010-02-19 | 2010-02-19 | |
| US61/306,047 | 2010-02-19 | ||
| PCT/US2011/024883 WO2011103089A1 (en) | 2010-02-19 | 2011-02-15 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117195A Division JP2015180679A (ja) | 2010-02-19 | 2015-06-10 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520424A JP2013520424A (ja) | 2013-06-06 |
| JP2013520424A5 true JP2013520424A5 (https=) | 2014-03-27 |
Family
ID=44483264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553967A Withdrawn JP2013520424A (ja) | 2010-02-19 | 2011-02-15 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| JP2015117195A Pending JP2015180679A (ja) | 2010-02-19 | 2015-06-10 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117195A Pending JP2015180679A (ja) | 2010-02-19 | 2015-06-10 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8653064B2 (https=) |
| EP (1) | EP2536279A4 (https=) |
| JP (2) | JP2013520424A (https=) |
| CN (2) | CN104031049A (https=) |
| BR (1) | BR112012020557A8 (https=) |
| CA (1) | CA2788774A1 (https=) |
| RU (1) | RU2012140021A (https=) |
| WO (1) | WO2011103089A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2535032C2 (ru) | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| BR112012020557A8 (pt) | 2010-02-19 | 2018-01-02 | Millennium Pharm Inc | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| US20130303519A1 (en) * | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN103724350A (zh) * | 2012-10-11 | 2014-04-16 | 韩冰 | 一类治疗脑性瘫痪的化合物及其用途 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| CN103408552B (zh) * | 2013-07-25 | 2015-07-01 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
| CN103408551B (zh) * | 2013-07-25 | 2015-08-05 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
| EP3076963A4 (en) | 2013-12-06 | 2017-09-13 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd30 antibodies |
| WO2017015316A1 (en) | 2015-07-21 | 2017-01-26 | Millennium Pharmaceuticals, Inc. | Administration of aurora kinase inhibitor and chemotherapeutic agents |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121941495A (zh) | 2023-10-03 | 2026-04-28 | 武田药品工业株式会社 | 用于治疗小细胞肺癌的阿立塞替和紫杉醇 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| NZ192803A (en) | 1979-02-07 | 1984-08-24 | Hoffmann La Roche | Pyrimido-2-benzazepines and pharmaceutical compositions |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0888350A1 (en) | 1996-03-08 | 1999-01-07 | Zeneca Limited | Azolobenzazepine derivatives as neurologically active agents |
| EP0946523A1 (en) | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| ES2191963T3 (es) | 1997-09-29 | 2003-09-16 | Meiji Seika Kaisha | Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos. |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| AU784971B2 (en) | 1999-08-11 | 2006-08-10 | Biogen Inc. | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| JP4364637B2 (ja) | 2001-08-09 | 2009-11-18 | アクテリオン ファーマシューティカルズ リミテッド | 新規なベンゾ縮合へテロ環化合物 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| AU2005243175B2 (en) | 2004-05-14 | 2011-12-01 | Millennium Pharmaceuticals, Inc. | Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase |
| CN101014603B (zh) * | 2004-05-14 | 2014-08-20 | 千禧药品公司 | 通过抑制极光激酶抑制有丝分裂的化合物和方法 |
| CN101084214A (zh) | 2004-11-17 | 2007-12-05 | 迈卡纳治疗股份有限公司 | 激酶抑制剂 |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| EA200870117A1 (ru) | 2005-12-23 | 2008-12-30 | Смитклайн Бичам Корпорейшн | Азаиндоловые ингибиторы аурора-киназ |
| JP2009542664A (ja) | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | Ｐ５３活性を増大させる置換されたピペリジンの使用の方法 |
| US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| RU2535032C2 (ru) | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| BR112012020557A8 (pt) | 2010-02-19 | 2018-01-02 | Millennium Pharm Inc | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio |
-
2011
- 2011-02-15 BR BR112012020557A patent/BR112012020557A8/pt not_active Application Discontinuation
- 2011-02-15 WO PCT/US2011/024883 patent/WO2011103089A1/en not_active Ceased
- 2011-02-15 CN CN201410055631.3A patent/CN104031049A/zh active Pending
- 2011-02-15 JP JP2012553967A patent/JP2013520424A/ja not_active Withdrawn
- 2011-02-15 CA CA2788774A patent/CA2788774A1/en not_active Abandoned
- 2011-02-15 EP EP11745114.6A patent/EP2536279A4/en not_active Withdrawn
- 2011-02-15 CN CN2011800099967A patent/CN102770024A/zh active Pending
- 2011-02-15 RU RU2012140021/04A patent/RU2012140021A/ru not_active Application Discontinuation
- 2011-02-15 US US13/027,523 patent/US8653064B2/en active Active
-
2014
- 2014-01-09 US US14/151,524 patent/US20140357622A1/en not_active Abandoned
-
2015
- 2015-06-10 JP JP2015117195A patent/JP2015180679A/ja active Pending
-
2016
- 2016-10-13 US US15/292,363 patent/US10017513B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520424A5 (https=) | ||
| RU2012140021A (ru) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ | |
| JP2014524442A5 (https=) | ||
| JP2018024682A5 (https=) | ||
| JP2021530565A5 (https=) | ||
| JP2016006096A5 (https=) | ||
| JP2012505235A5 (https=) | ||
| NZ742200A (en) | Treatment of osteoarthritis | |
| RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| JP2012153722A5 (https=) | ||
| JP2017537969A5 (https=) | ||
| SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
| JP2014518266A5 (https=) | ||
| JP2014162794A5 (https=) | ||
| JP2013543867A5 (https=) | ||
| JP2017039702A5 (https=) | ||
| JP2012506872A5 (https=) | ||
| RU2012146517A (ru) | Соли ральтегравира и их кристаллические формы | |
| JP2016503414A5 (https=) | ||
| JP2019516749A5 (https=) | ||
| JP2013503134A5 (https=) | ||
| JP2012509279A5 (https=) | ||
| MA30276B1 (fr) | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
| JP2011515421A5 (https=) | ||
| JP2015516425A5 (https=) |